阿尔茨海默氏症,临床试验 z-bo 2020-09-17 347

　　According to Bloomberg News, Swiss pharmaceutical giant Roche recently announced that due to its failure to prevent Alzheimer's disease, it has completed a phase III clinical trial of the single-drug antibody Gantenermab. It is believed that part of the cause of Alzheimer's disease is the accumulation of beta amyloid plaques in the brain.

　　Gantenerumab is a drug that helps patients with early disease before symptoms worsen. Although previous experiments have achieved good results, the antibody still cannot effectively prevent the formation of protein plaques. How to treat this debilitating nervous system disease and whether protein plaques are the cause of this disease has sparked new controversy.